|
Form 4 Filings | Insider Buys | Significant Buys |
Penny Stocks Insider Buying |
Insider Sales |
| Insider Buy Sell Ratios | Stock Options |
Insider Trading Stock Screener |
Insider Trading Graph View |
Insider Watch |
Insider Trading - CRISPR Therapeutics AG (CRSP)
|
|
"Insiders might sell their shares for any number of reasons, but they buy them for only one:
they think the price will rise"
- Peter Lynch What is insider trading>> |
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2018-07-03 Sale |
2018-07-05 6:25 pm |
CRISPR Therapeutics AG | CRSP | CAGNONI PABLO J Director |
7,500 | $62 | $465,000 | 88,017 (Direct) |
View |
| 2018-06-05 Sale |
2018-06-07 4:36 pm |
CRISPR Therapeutics AG | CRSP | EMSTER KURT VON Director |
920 | $12.51 | $11,509 | 273,417 (Direct Indirect) |
View |
| 2018-06-01 Sale |
2018-06-05 8:20 pm |
CRISPR Therapeutics AG | CRSP | Kulkarni Samarth CEO |
15,000 | $69.36 | $1,040,400 | 264,558 (Direct) |
View |
| 2018-05-17 Sale |
2018-05-21 4:54 pm |
CRISPR Therapeutics AG | CRSP | Novak Rodger President |
75,000 | $60 | $4,500,000 | 1,223,007 (Direct) |
View |
| 2018-05-15 Sale |
2018-05-17 5:15 pm |
CRISPR Therapeutics AG | CRSP | Bolzon Bradley J PhD Director |
44,000 | $57.99 | $2,551,440 | 641,014 (Direct Indirect) |
View |
| 2018-05-15 Sale |
2018-05-17 5:11 pm |
CRISPR Therapeutics AG | CRSP | Woiwode Thomas Director |
44,000 | $57.99 | $2,551,440 | 641,014 (Direct Indirect) |
View |
| 2018-05-11 Sale |
2018-05-15 8:04 pm |
CRISPR Therapeutics AG | CRSP | EMSTER KURT VON Director |
650,000 | $54.39 | $35,352,456 | 1,773,725 (Indirect) |
View |
| 2018-05-07 Sale |
2018-05-09 5:15 pm |
CRISPR Therapeutics AG | CRSP | Woiwode Thomas Director |
121,362 | $50.39 | $6,115,873 | 1,199,784 (Indirect Direct) |
View |
| 2018-05-07 Sale |
2018-05-09 5:14 pm |
CRISPR Therapeutics AG | CRSP | Bolzon Bradley J PhD Director |
128,950 | $50.39 | $6,497,892 | 1,199,784 (Indirect Direct) |
View |
| 2018-04-30 Sale |
2018-05-02 6:00 pm |
CRISPR Therapeutics AG | CRSP | Woiwode Thomas Director |
30,566 | $50.29 | $1,537,138 | 1,297,334 (Direct Indirect) |
View |
| 2018-04-30 Sale |
2018-05-02 6:00 pm |
CRISPR Therapeutics AG | CRSP | Bolzon Bradley J PhD Director |
30,566 | $50.29 | $1,537,138 | 1,297,334 (Direct Indirect) |
View |
| 2018-04-26 Sale |
2018-04-30 8:58 pm |
CRISPR Therapeutics AG | CRSP | Bolzon Bradley J PhD Director |
222,258 | $50.11 | $11,136,437 | 1,334,430 (Indirect) |
View |
| 2018-04-26 Sale |
2018-04-30 8:57 pm |
CRISPR Therapeutics AG | CRSP | Woiwode Thomas Director |
222,258 | $50.11 | $11,136,437 | 1,334,430 (Indirect) |
View |
| 2018-04-24 Sale |
2018-04-26 5:01 pm |
CRISPR Therapeutics AG | CRSP | Woiwode Thomas Director |
22,841 | $50.99 | $1,164,655 | 1,519,505 (Indirect) |
View |
| 2018-04-24 Sale |
2018-04-26 4:57 pm |
CRISPR Therapeutics AG | CRSP | Bolzon Bradley J PhD Director |
22,841 | $50.99 | $1,164,655 | 1,519,505 (Indirect) |
View |
| 2018-04-24 Sale |
2018-04-26 4:44 pm |
CRISPR Therapeutics AG | CRSP | Versant Venture Capital V L.P. Versant Ventures V LLC Versant Affiliates Fund V L.P. Versant Ophthalmic Affiliates I L.P. Versant Venture Capital V (Canada) LP 10% Owner |
22,841 | $50.99 | $1,164,655 | 1,519,505 (Indirect) |
View |
| 2018-04-20 Sale |
2018-04-24 7:44 pm |
CRISPR Therapeutics AG | CRSP | Versant Venture Capital IV L.P. Versant Side Fund IV L.P. Versant Ventures IV LLC Versant Venture Capital V L.P. Versant Affiliates Fund V L.P. Versant Ophthalmic Affiliates I L.P. Versant Venture Capital V (Canada) LP 10% Owner |
101,994 | $50.68 | $5,168,901 | 2,238,979 (Indirect) |
View |
| 2018-04-20 Sale |
2018-04-24 7:42 pm |
CRISPR Therapeutics AG | CRSP | Woiwode Thomas Director |
101,994 | $50.68 | $5,168,901 | 2,238,979 (Indirect Direct) |
View |
| 2018-04-20 Sale |
2018-04-24 7:41 pm |
CRISPR Therapeutics AG | CRSP | Bolzon Bradley J PhD Director |
101,994 | $50.68 | $5,168,901 | 2,238,979 (Indirect Direct) |
View |
| 2018-01-05 Purchase |
2018-01-30 2:21 pm |
CRISPR Therapeutics AG | CRSP | BAYER AKTIENGESELLSCHAFT Bayer Global Investments B.V. 10% Owner |
527,472 | $22.75 | $11,999,988 | 5,632,802 (Indirect) |
View |
| 2018-01-16 Sale |
2018-01-18 5:38 pm |
CRISPR Therapeutics AG | CRSP | Dylan-Hyde Tyler Chief Legal Officer |
66,000 | $28.03 | $1,850,255 | 45,094 (Direct) |
View |
| 2018-01-05 Purchase |
2018-01-11 9:00 pm |
CRISPR Therapeutics AG | CRSP | EMSTER KURT VON Director |
65,934 | $22.75 | $1,499,998 | 1,887,202 (Indirect) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2018-07-03 Exercise |
2018-07-05 6:25 pm |
N/A N/A |
CRISPR Therapeutics AG | CRSP | CAGNONI PABLO J Director |
5,816 | $5.59 | 88,017 (Direct) |
View |
| 2018-07-03 Exercise |
2018-07-05 6:25 pm |
N/A N/A |
CRISPR Therapeutics AG | CRSP | CAGNONI PABLO J Director |
1,684 | $5.59 | 88,017 (Direct) |
View |
| 2018-07-03 Exercise |
2018-07-05 6:25 pm |
N/A 2025-11-04 |
CRISPR Therapeutics AG | CRSP | CAGNONI PABLO J Director |
5,816 | $5.59 | 88,017 (Direct) |
View |
| 2018-07-03 Exercise |
2018-07-05 6:25 pm |
N/A 2025-11-04 |
CRISPR Therapeutics AG | CRSP | CAGNONI PABLO J Director |
1,684 | $5.59 | 88,017 (Direct) |
View |
| 2018-06-15 Option Award |
2018-06-19 4:55 pm |
N/A 2028-06-15 |
CRISPR Therapeutics AG | CRSP | George Simeon Director |
15,000 | $59.31 | 15,000 (Direct) |
View |
| 2018-06-15 Option Award |
2018-06-18 4:21 pm |
N/A 2028-06-15 |
CRISPR Therapeutics AG | CRSP | EMSTER KURT VON Director |
15,000 | $59.31 | 15,000 (Direct) |
View |
| 2018-06-15 Option Award |
2018-06-15 9:46 pm |
N/A 2028-06-15 |
CRISPR Therapeutics AG | CRSP | Behbahani Ali Director |
15,000 | $59.31 | 15,000 (Direct) |
View |
| 2018-06-15 Option Award |
2018-06-15 9:41 pm |
N/A 2028-06-15 |
CRISPR Therapeutics AG | CRSP | KASINGER JAMES R. General Counsel and Secretary |
32,000 | $59.31 | 32,000 (Direct) |
View |
| 2018-06-15 Option Award |
2018-06-15 9:40 pm |
N/A 2028-06-15 |
CRISPR Therapeutics AG | CRSP | Bolzon Bradley J PhD Director |
30,000 | $59.31 | 30,000 (Indirect) |
View |
| 2018-06-15 Option Award |
2018-06-15 9:39 pm |
N/A 2028-06-15 |
CRISPR Therapeutics AG | CRSP | Woiwode Thomas Director |
30,000 | $59.31 | 30,000 (Indirect) |
View |
| 2018-06-15 Option Award |
2018-06-15 9:38 pm |
N/A 2028-06-15 |
CRISPR Therapeutics AG | CRSP | Ho Tony W See Remarks |
43,000 | $59.31 | 43,000 (Direct) |
View |
| 2018-06-15 Option Award |
2018-06-15 9:37 pm |
N/A 2028-06-15 |
CRISPR Therapeutics AG | CRSP | TOMSICEK MICHAEL JOHN CFO |
20,760 | $59.31 | 20,760 (Direct) |
View |
| 2018-06-15 Option Award |
2018-06-15 9:36 pm |
N/A 2028-06-15 |
CRISPR Therapeutics AG | CRSP | Kulkarni Samarth CEO |
109,000 | $59.31 | 109,000 (Direct) |
View |
| 2018-06-15 Option Award |
2018-06-15 9:35 pm |
N/A 2018-06-15 |
CRISPR Therapeutics AG | CRSP | CAGNONI PABLO J Director |
15,000 | $59.31 | 15,000 (Direct) |
View |
| 2018-06-05 Exercise |
2018-06-07 4:36 pm |
N/A N/A |
CRISPR Therapeutics AG | CRSP | EMSTER KURT VON Director |
2,000 | $5.75 | 273,417 (Indirect) |
View |
| 2018-06-05 Exercise |
2018-06-07 4:36 pm |
2013-09-30 2018-09-30 |
CRISPR Therapeutics AG | CRSP | EMSTER KURT VON Director |
2,000 | $5.75 | 273,417 (Indirect) |
View |
| 2018-06-01 Exercise |
2018-06-05 8:20 pm |
N/A N/A |
CRISPR Therapeutics AG | CRSP | Kulkarni Samarth CEO |
15,000 | $1.81 | 264,558 (Direct) |
View |
| 2018-06-01 Tax Withholding |
2018-06-05 8:20 pm |
N/A N/A |
CRISPR Therapeutics AG | CRSP | Kulkarni Samarth CEO |
741 | $67.13 | 264,558 (Direct) |
View |
| 2018-06-01 Exercise |
2018-06-05 8:20 pm |
N/A 2025-09-10 |
CRISPR Therapeutics AG | CRSP | Kulkarni Samarth CEO |
15,000 | $1.81 | 264,558 (Direct) |
View |
| 2018-05-17 Exercise |
2018-05-21 4:54 pm |
N/A N/A |
CRISPR Therapeutics AG | CRSP | Novak Rodger President |
35,240 | $1.81 | 1,223,007 (Direct) |
View |
| 2018-05-17 Exercise |
2018-05-21 4:54 pm |
N/A N/A |
CRISPR Therapeutics AG | CRSP | Novak Rodger President |
39,760 | $14 | 1,223,007 (Direct) |
View |
| 2018-05-17 Exercise |
2018-05-21 4:54 pm |
N/A 2025-09-10 |
CRISPR Therapeutics AG | CRSP | Novak Rodger President |
35,240 | $1.81 | 1,223,007 (Direct) |
View |
| 2018-05-17 Exercise |
2018-05-21 4:54 pm |
N/A 2016-10-18 |
CRISPR Therapeutics AG | CRSP | Novak Rodger President |
39,760 | $14 | 1,223,007 (Direct) |
View |
| 2018-05-14 Other |
2018-05-15 4:32 pm |
N/A N/A |
CRISPR Therapeutics AG | CRSP | Behbahani Ali Director |
199 | $0 | 199 (Direct) |
View |
| 2018-04-20 Other |
2018-04-24 7:44 pm |
N/A N/A |
CRISPR Therapeutics AG | CRSP | Versant Venture Capital IV L.P. Versant Side Fund IV L.P. Versant Ventures IV LLC Versant Venture Capital V L.P. Versant Affiliates Fund V L.P. Versant Ophthalmic Affiliates I L.P. Versant Venture Capital V (Canada) LP 10% Owner |
497,053 | $0 | 2,238,979 (Indirect) |
View |
| 2018-04-20 Other |
2018-04-24 7:44 pm |
N/A N/A |
CRISPR Therapeutics AG | CRSP | Versant Venture Capital IV L.P. Versant Side Fund IV L.P. Versant Ventures IV LLC Versant Venture Capital V L.P. Versant Affiliates Fund V L.P. Versant Ophthalmic Affiliates I L.P. Versant Venture Capital V (Canada) LP 10% Owner |
2,947 | $0 | 2,238,979 (Indirect) |
View |
| 2018-04-20 Other |
2018-04-24 7:44 pm |
N/A N/A |
CRISPR Therapeutics AG | CRSP | Versant Venture Capital IV L.P. Versant Side Fund IV L.P. Versant Ventures IV LLC Versant Venture Capital V L.P. Versant Affiliates Fund V L.P. Versant Ophthalmic Affiliates I L.P. Versant Venture Capital V (Canada) LP 10% Owner |
92,918 | $0 | 2,238,979 (Indirect) |
View |
| 2018-04-20 Other |
2018-04-24 7:44 pm |
N/A N/A |
CRISPR Therapeutics AG | CRSP | Versant Venture Capital IV L.P. Versant Side Fund IV L.P. Versant Ventures IV LLC Versant Venture Capital V L.P. Versant Affiliates Fund V L.P. Versant Ophthalmic Affiliates I L.P. Versant Venture Capital V (Canada) LP 10% Owner |
92,918 | $0 | 2,238,979 (Indirect) |
View |
| 2018-04-20 Other |
2018-04-24 7:42 pm |
N/A N/A |
CRISPR Therapeutics AG | CRSP | Woiwode Thomas Director |
497,053 | $0 | 2,238,979 (Indirect) |
View |
| 2018-04-20 Other |
2018-04-24 7:42 pm |
N/A N/A |
CRISPR Therapeutics AG | CRSP | Woiwode Thomas Director |
2,947 | $0 | 2,238,979 (Indirect) |
View |
| 2018-04-20 Other |
2018-04-24 7:42 pm |
N/A N/A |
CRISPR Therapeutics AG | CRSP | Woiwode Thomas Director |
92,918 | $0 | 2,238,979 (Indirect) |
View |
| 2018-04-20 Other |
2018-04-24 7:42 pm |
N/A N/A |
CRISPR Therapeutics AG | CRSP | Woiwode Thomas Director |
92,918 | $0 | 2,238,979 (Indirect) |
View |
| 2018-04-20 Other |
2018-04-24 7:42 pm |
N/A N/A |
CRISPR Therapeutics AG | CRSP | Woiwode Thomas Director |
2,323 | $0 | 2,238,979 (Direct) |
View |
| 2018-04-20 Other |
2018-04-24 7:41 pm |
N/A N/A |
CRISPR Therapeutics AG | CRSP | Bolzon Bradley J PhD Director |
497,053 | $0 | 2,238,979 (Indirect) |
View |
| 2018-04-20 Other |
2018-04-24 7:41 pm |
N/A N/A |
CRISPR Therapeutics AG | CRSP | Bolzon Bradley J PhD Director |
2,947 | $0 | 2,238,979 (Indirect) |
View |
| 2018-04-20 Other |
2018-04-24 7:41 pm |
N/A N/A |
CRISPR Therapeutics AG | CRSP | Bolzon Bradley J PhD Director |
92,918 | $0 | 2,238,979 (Indirect) |
View |
| 2018-04-20 Other |
2018-04-24 7:41 pm |
N/A N/A |
CRISPR Therapeutics AG | CRSP | Bolzon Bradley J PhD Director |
92,918 | $0 | 2,238,979 (Indirect) |
View |
| 2018-04-20 Other |
2018-04-24 7:41 pm |
N/A N/A |
CRISPR Therapeutics AG | CRSP | Bolzon Bradley J PhD Director |
16,262 | $0 | 2,238,979 (Direct) |
View |
| 2018-04-16 Option Award |
2018-04-18 4:50 pm |
N/A 2027-12-01 |
CRISPR Therapeutics AG | CRSP | Kulkarni Samarth CEO |
75,000 | $19.12 | 150,000 (Direct) |
View |
| 2018-03-12 Option Award |
2018-03-14 9:39 pm |
N/A 2027-12-01 |
CRISPR Therapeutics AG | CRSP | Kulkarni Samarth CEO |
75,000 | $19.12 | 75,000 (Direct) |
View |
| 2018-03-07 Option Award |
2018-03-09 4:54 pm |
N/A 2028-03-07 |
CRISPR Therapeutics AG | CRSP | Ho Tony W See Remarks |
53,000 | $51.49 | 53,000 (Direct) |
View |
| 2018-03-07 Option Award |
2018-03-09 4:50 pm |
N/A 2028-03-07 |
CRISPR Therapeutics AG | CRSP | Kulkarni Samarth CEO |
136,000 | $51.49 | 136,000 (Direct) |
View |
| 2018-03-07 Option Award |
2018-03-09 4:50 pm |
N/A 2028-03-07 |
CRISPR Therapeutics AG | CRSP | KASINGER JAMES R. General Counsel and Secretary |
40,000 | $51.49 | 40,000 (Direct) |
View |
| 2018-03-07 Option Award |
2018-03-09 4:50 pm |
N/A 2028-03-07 |
CRISPR Therapeutics AG | CRSP | TOMSICEK MICHAEL JOHN CFO |
25,000 | $51.49 | 25,000 (Direct) |
View |
| 2018-01-16 Exercise |
2018-01-18 5:38 pm |
N/A N/A |
CRISPR Therapeutics AG | CRSP | Dylan-Hyde Tyler Chief Legal Officer |
1,110 | $12.57 | 45,094 (Direct) |
View |
| 2018-01-16 Exercise |
2018-01-18 5:38 pm |
N/A N/A |
CRISPR Therapeutics AG | CRSP | Dylan-Hyde Tyler Chief Legal Officer |
19,890 | $12.57 | 45,094 (Direct) |
View |
| 2018-01-16 Exercise |
2018-01-18 5:38 pm |
N/A 2026-07-15 |
CRISPR Therapeutics AG | CRSP | Dylan-Hyde Tyler Chief Legal Officer |
1,110 | $12.57 | 45,094 (Direct) |
View |
| 2018-01-16 Exercise |
2018-01-18 5:38 pm |
N/A 2026-07-15 |
CRISPR Therapeutics AG | CRSP | Dylan-Hyde Tyler Chief Legal Officer |
19,890 | $12.57 | 45,094 (Direct) |
View |
|
© 2005-2018 SecForm4.Com All rights reserved. Archives: 2018 2017 2016 2015 2014 2013 ... Wed, 18 Jul 2018 03:35:19 -0500 |
SEC is the U.S. Securities and Exchange Commission. EDGAR is a trademark of the SEC.
SecForm4.Com is not affiliated with or approved by the U.S. Securities and Exchange Commission (SEC). Terms of Use | Privacy Statement | |